97.5% is owned by Sidney and his wife and couple others. He has been personally funding the company. 2.5% or 88M is the public float. This is why it moves so easily and is volatile. Sidney and wife have 20M invested. There is a potential for a PP but for now Sidney just continuing to finance the company until we see otherwise. In January 2016 I believe they downsized the company to put all available resources to get FDA clearance. There has been no dilution as the share structure has not changed since I have been following it when they got clearance. With the minority ownership so low this could easily see big spikes with the right news as Sidney is not selling. The share structure is set up to prevent any hostile takeover.
They are very close to some major developments happening now as far as being able to understand how they will monetize this product. All you have to do is read between the lines on the steps they are taking. I would recommend watching the videos very closely. Understanding reimbursements in social medicine. Understand data on meds that could be collected and the value that would have to big pharma. A understanding on how this could elevate diabetes care on a very large scale.
Possible news would be patent award. Who they may co market with. Any additional studies with the initial roll out. Changes in law in the US on who can prescribe the diabetes meds. California has already changed laws and Oregon has to some degree. In Canada pharmacists can prescribe as well as Dr's. This platform is going to be very disruptive but I believe the right big players will see enough benefit to do the heavy lifting to push for major adoption in geographies outside of the US. Who are those big players? When it comes to social medicine the biggest player of all is the government.
News 
Market Data 
Discover 
AI
